ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Semaglutide

Also written as “semaglutide”, “Oral semaglutide” and “Semaglutide 2.4 mg”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Diabetes Mellitus · Non-alcoholic Fatty Liver Disease · Alzheimer Disease, led by 11 companies.

Drug pageSemaglutide: every studyMany companies study it; this page follows only the 163 they lead. All 451 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jul 11, 2018163 company-led studies, 15 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordisk1518 open or runningphase 4since Jul 11, 2018Jun 11, 2008Dec 13, 2026phase 1 · NCT07225816
CSPC Pharmaceutical Groupits history only20 open or runningphase 3since Nov 30, 2023Nov 30, 2023none ahead
Hangzhou Jiuyuan Gene Engineeringits history only21 open or runningphase 3since Feb 20, 2023Feb 20, 2023none ahead
Chengdu Brilliant Pharmaceuticalits history only11 open or runningphase 3since Mar 18, 2024Mar 18, 2024none ahead
Geropharmits history only10 open or runningphase 1since Jul 4, 2024Jul 4, 2024none ahead
Gila Therapeuticsits history only11 open or runningphase 4since Apr 17, 2026Apr 17, 2026May 2027phase 4 · NCT07728383
Korea United Pharm.its history only11 open or runningphase 1since Oct 28, 2026Oct 28, 2026Nov 1, 2027phase 1 · NCT07935200
Qilu Pharmaceuticalits history only11 open or runningphase 3since Jul 11, 2023Jul 11, 2023none ahead
Shanghai World Leader Pharmaceuticalits history only11 open or runningphase 1since Jan 28, 2026Jan 28, 2026none ahead
Sino Biopharmaceuticalits history only10 open or runningphase 3since Dec 13, 2024Dec 13, 2024none ahead

Also a collaborator on its studies: Celerion and Avance Clinical Pty.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Novo Nordisk only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 45 studies since Sep 27, 2019.

  1. May 26, 20232 phase 3 studiesNCT05890976, NCT05891496
  2. Aug 10, 2023Phase 1 study in Healthy ParticipantsNCT05996874 · 121 enrolled · Germany
  3. Sep 11, 2023Phase 3 study in OverweightNCT06041217 · 242 enrolled · China, Taiwan
  4. Oct 9, 2023Phase 3 study in Diabetes Mellitus, Type 2NCT06083675 · United States, Brazil, Bulgaria and more
  5. Oct 18, 2023Phase 1 study in Healthy ParticipantsNCT06097390 · 121 enrolled · Canada
  6. Feb 12, 2024Phase 1 study in OverweightNCT06267092 · 164 enrolled · Germany
  7. May 7, 2024Phase 2 study in Alcohol-related Liver DiseaseNCT06409130 · 270 enrolled · United States, Australia, Bulgaria and more
  8. Aug 22, 2024Phase 4 study in ObesityNCT06571383 · 500 enrolled · United States, Belgium, Canada and more
  9. Oct 13, 2024Phase 1 study in Healthy Volunteers Type 2 DiabetesNCT06642584 · 90 enrolled · Canada
  10. Nov 5, 2025Phase 1 study in ObesityNCT07225816 · 71 planned · United States
  11. Nov 27, 2025Phase 3 study in Diabetes Mellitus, Type 2NCT07271251 · 267 enrolled · Japan
  12. Aug 13, 2026Phase 3 study in OverweightNCT07770841 · 450 planned · United States, Belgium, Bulgaria and more
  13. Sep 22, 2026Phase 1 study in ObesityNCT07845578 · 60 planned · Austria
  14. Oct 21, 2026Phase 4 study in Renal Insufficiency, ChronicNCT07900438 · 300 planned · China

Ahead

  1. Dec 13, 2026Primary completion: phase 1 study in ObesityNCT07225816
  2. Sep 11, 2027Primary completion: phase 1 study in ObesityNCT07845578
  3. Feb 22, 2028Primary completion: phase 3 study in OverweightNCT07770841
  4. Nov 15, 2028Primary completion: phase 4 study in ObesityNCT06571383

TargetBeta

GLP1R →read by rule
“A glucagon-like peptide-1 (GLP-1) receptor agonist that is 94% homologous to human GLP-1 (7-37), with antihyperglycemic and appetite regulating activities”NCIt, by rule
“Glucagon-like peptide 1 receptor agonist”ChEMBL 37, by rule

Other programs on GLP1R

ProgramCompanyFurthest phaseStudies
LiraglutideruleNovo Nordiskphase 4116
TirzepatideruleEli Lillyphase 472
dulaglutideruleEli Lillyphase 447
orforglipronruleEli Lillyphase 350
zenagamtideNovo Nordiskphase 336
survodutideBoehringer Ingelheimphase 335
retatrutideruleEli Lillyphase 333
mazdutideruleInnovent Biologicsphase 327
bofanglutideruleGan & Lee Pharmaceuticalsphase 325
berobenatidePfizerphase 323
brenipatideEli Lillyphase 319
SafiglipronJiangsu HengRui Medicinephase 319

Studies

The newest 60 of 151 Novo Nordisk leads. Each opens its study page. Every study on its drug page →

StudyPhaseStatusPrimary completionSize
NCT07900438Renal Insufficiency, Chronic · China4RecruitingDec 20, 2029300
NCT07845578Obesity · Austria1RecruitingSep 11, 202760
NCT07770841Overweight · United States, Belgium, Bulgaria and more3RecruitingFeb 22, 2028450
NCT07271251Diabetes Mellitus, Type 2 · Japan3CompletedJun 29, 2026267
NCT07225816Obesity · United States1RecruitingDec 13, 202671
NCT06642584Healthy Volunteers Type 2 Diabetes · Canada1CompletedJul 10, 202590
NCT06571383Obesity · United States, Belgium, Canada and more4Active, not recruitingNov 15, 2028500
NCT06409130Alcohol-related Liver Disease · United States, Australia, Bulgaria and more2CompletedNov 21, 2025270
NCT06267092Overweight · Germany1CompletedApr 7, 2025164
NCT06097390Healthy Participants · Canada1CompletedFeb 22, 2024121
NCT06083675Diabetes Mellitus, Type 2 · United States, Brazil, Bulgaria and more3WithdrawnJan 24, 20250
NCT06041217Overweight · China, Taiwan3CompletedApr 2, 2025242
NCT05996874Healthy Participants · Germany1CompletedApr 18, 2024121
NCT05891496Alzheimer Disease · United States, Canada, Denmark and more3CompletedAug 19, 202423
NCT05890976Overweight · China3CompletedJan 16, 2025200
NCT05813912Diabetes Mellitus, Type 2 · Czechia, Malaysia, Poland and more3CompletedApr 14, 2025148
NCT05784402Healthy Participants · United States, Canada1CompletedFeb 23, 2024264
NCT05726227Obesity · United States, Austria, Belgium and more3Active, not recruitingOct 15, 2025212
NCT05689099Diabetes Mellitus, Type 2 · United States1CompletedMay 30, 202320
NCT05649137Obesity · United States, Bulgaria, Canada and more3CompletedOct 28, 2024512
NCT05646706Obesity · United States, Bulgaria, Canada and more3CompletedOct 30, 20241,407
NCT05579249Obesity · United States4CompletedNov 27, 2024500
NCT05564117Overweight · United States, Canada, Germany and more3CompletedApr 18, 2024307
NCT05533632Diabetes Mellitus, Type 2 · Chile4CompletedJan 18, 2024104
NCT05514535Diabetes Mellitus, Type 2 · United States, Czechia, Greece and more3CompletedMar 5, 2025573
NCT05486065Diabetes Mellitus, Type 2 · United States, Greece, Hungary and more2CompletedOct 12, 2023245
NCT05478252Diabetes Mellitus, Type 2 · United States, Canada, Poland and more3CompletedAug 9, 2023388
NCT05444153Diabetes Mellitus, Type 23WithdrawnOct 2, 20240
NCT05429593Healthy Volunteers · Germany1CompletedMar 10, 2023152
NCT05352815Diabetes Mellitus, Type 2 · United States, Australia, Belgium and more3CompletedMar 19, 20241,291
NCT05227196Diabetes Mellitus, Type 2 · United States, Canada1CompletedJun 28, 2023546
NCT05232708Diabetes Mellitus · United Kingdom1CompletedAug 30, 202218
NCT05132088Overweight · Japan, South Korea3CompletedJul 11, 2023201
NCT05064735Obesity · United States, Canada, Colombia and more3CompletedJul 24, 2023407
NCT05040971Obesity · Canada, Denmark, Finland and more3CompletedJan 6, 2023207
NCT05035095Obesity · United States, Canada, Denmark and more3CompletedMar 24, 2023667
NCT05035082Diabetes Mellitus, Type 2 · United States4CompletedJun 18, 20251,018
NCT04998136Obesity · South Korea, Thailand3CompletedOct 16, 2023150
NCT04940078Obesity · Canada, Denmark1CompletedJan 19, 202240
NCT04916470Diabetes Mellitus · United States, Argentina, Austria and more3CompletedOct 11, 2023617
NCT04865770Diabetes Mellitus, Type 2 · United States, Canada, Denmark and more3CompletedNov 21, 2024106
NCT04822181Non-alcoholic Fatty Liver Disease · United States, Argentina, Australia and more3Active, not recruitingApr 25, 20291,205
NCT04817644Diabetes Mellitus, Type 2 · United States1CompletedMay 26, 202314
NCT04788511Obesity · United States, Argentina, Australia and more3CompletedApr 18, 2023529
NCT04777409Early Alzheimer´s Disease · United States, Argentina, Australia and more3CompletedSep 15, 20251,840
NCT04777396Alzheimer Disease · United States, Argentina, Australia and more3CompletedSep 16, 20251,840
NCT04707469Diabetes Mellitus, Type 2 · United States, Australia, Bulgaria and more3CompletedMar 7, 20231,606
NCT04596631Diabetes Mellitus, Type 2 · United States, Australia, Austria and more3CompletedApr 29, 2025132
NCT04560998Diabetes Mellitus, Type 2 · United States, Austria, Belgium and more3CompletedJun 5, 2024792
NCT04524832Diabetes Mellitus, Type 2 · Germany1CompletedFeb 25, 2022290
NCT04513704Healthy Volunteers Type 2 Diabetes · United Kingdom1CompletedApr 20, 2021156
NCT04287179Diabetes Mellitus, Type 2 · United States, Austria, Finland and more3WithdrawnNov 16, 20200
NCT04251156Overweight · Brazil, China, Hong Kong and more3CompletedAug 23, 2022375
NCT04238962Overweight · Germany1CompletedOct 20, 2020111
NCT04228354Overweight · Germany1CompletedJun 1, 202028
NCT04189848Diabetes Mellitus, Type 2 · Netherlands4CompletedJan 29, 2020104
NCT04187300Overweight · Germany1CompletedSep 23, 202068
NCT04152915Diabetes Mellitus, Type 2 · Germany1CompletedMay 25, 202068
NCT04143945Healthy Volunteers Diabetes Mellitus, Type 2 · Netherlands2CompletedJan 4, 2020104
NCT04109547Diabetes Mellitus, Type 2 · Algeria, China, Hungary and more3CompletedSep 23, 2021521

How it is read

Names in the registry

  • “semaglutide”, 83 entries
  • “Semaglutide”, 66 entries
  • “Oral semaglutide”, 11 entries
  • “Semaglutide 2.4 mg”, 3 entries
  • “Semaglutide J”, 3 entries

Codes read as this program: UI112, HD1916.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.